Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,108.40
(
0.00%
)
US TECH 100
26,368.00
(
1.19%
)
Dow Jones
49,310.32
(
0.00%
)
Brent Oil
99.75
(
-1.44%
)
Bitcoin
78,381.05
(
0.13%
)
News Focus
News Focus
Post# of 257442
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122884
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: Daniel_Ward post# 204585

Wednesday, 02/01/2017 6:39:08 PM

Wednesday, February 01, 2017 6:39:08 PM

Post# of 257442
AVIR -22%/AH on failed phase-2 trial in RSV:

http://finance.yahoo.com/news/aviragen-therapeutics-announces-top-line-213000963.html

Aviragen Therapeutics, Inc…today announced top-line data from its double-blind, placebo-controlled Phase 2a study of BTA585 in adults challenged intranasally with respiratory syncytial virus (RSV). The data indicate there was not a significant reduction in the primary endpoint, which was viral load. The overall safety profile of BTA585 was favorable and consistent across treatment groups.

When an anitiviral doesn’t reduce viral load, you have a problem.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today